Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement
Open Access
- 14 February 2019
- journal article
- editorial
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 104 (5) , e222-e223
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Mechanistic Physiologically Based Pharmacokinetic Modeling of the Dissolution and Food Effect of a Biopharmaceutics Classification System IV Compound—The Venetoclax StoryJournal of Pharmaceutical Sciences, 2018
- Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy VolunteersClinical Drug Investigation, 2016
- Pharmacokinetics of Venetoclax, a Novel BCL‐2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non‐Hodgkin LymphomaThe Journal of Clinical Pharmacology, 2016
- The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanismBlood, 2016
- Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemiaBlood, 2016
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2016
- Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemiaHaematologica, 2016
- Extramedullary chronic lymphocytic leukemia: Systematic analysis of cases reported between 1975 and 2012Leukemia Research, 2014
- Chronic lymphocytic leukemia with central nervous system involvement: report of two cases with a comprehensive literature reviewJournal of Neuro-Oncology, 2011